IDEXX Laboratories

IDXX · NASDAQ

$557.93+$2.13 (+0.38%)TodayMarket closed · Oct 20, 7:36 PM ET

Prev close $555.80

IDXX analyst rating

BuyConsensus of 9 analysts over the last 12 months. 56% rate it a buy.

Strong buy0
Buy5
Hold4
Underperform0
Sell0

12-month price target · 16 analysts

Average $723.29 (+29.6% upside)

Low: $477.17
Now: $557.93
High: $845.25

Upgrades and downgrades

The latest rating actions, newest first

IDXX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
JP Morgan	Oct 16, 2026	Maintains	Overweight	$775.00 → $750.00	65%
Keybanc	Oct 12, 2026	Initiates	Sector Weight	—	50%
Barclays	Aug 11, 2026	Maintains	Overweight	$800.00 → $710.00	53%
UBS	Aug 5, 2026	Maintains	Neutral	$620.00 → $670.00	83%
Citigroup	Aug 5, 2026	Maintains	Neutral	$650.00 → $670.00	44%
UBS	Jul 27, 2026	Maintains	Neutral	$640.00 → $620.00	83%
UBS	Apr 28, 2026	Maintains	Neutral	$730.00 → $640.00	83%
Citigroup	Apr 15, 2026	Initiates	Neutral	$650.00	44%
Stifel	Mar 31, 2026	Maintains	Buy	$775.00 → $675.00	55%
Piper Sandler	Feb 9, 2026	Maintains	Neutral	$775.00 → $750.00	58%

The case for and against

Updated Jul 21, 2026

Bull case

IDEXX Laboratories is a top-performing company in the animal health industry with a global presence and a diverse product portfolio including diagnostic test kits, lab services, and software solutions. The company has consistently achieved strong financial results with double-digit EPS growth and is well-positioned to benefit from the growing trend of "humanization of pets". While there are potential risks, such as negative media attention, the company's CEO transition and new product launches are expected to drive further growth. Additionally, the industry itself is expected to rebound, which could further boost IDEXX's performance.

Bear case

IDEXX Laboratories is a company with a strong product line and high recurring revenue, specifically in its core companion animal group segment, which represents 90% of its total revenue. While the animal health industry has significant growth potential, IDXX may face challenges such as potential supply chain disruptions and government regulations. However, with its market leadership and investments in research and development, IDXX is well-positioned for long-term secular growth.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.